XPC and urinary bladder carcinoma: Overall, there is statistically significant association was found between XPC Lys939Gln polymorphism and the bladder cancer risk in homozygous model (OR = 1.39, 95% CI = 1.08-1.79) (Figure 1), heterozygous model (Gln/Gln vs Gln/Lys: OR = 1.42, 95% CI = 1.11-1.83) (Figure 2), and allele comparison model (OR = 1.12, 95% CI = 1.003-1.24) (Figure 3), but not in other models (Table 2).